Transaction #18406 · Form 4 · 0001193125-25-315989
4D Molecular Therapeutics, Inc. · Stock award · Stock Option (Right to Buy)
4D Molecular Therapeutics, Inc. · Transacted December 9, 2025 · Filed December 11, 2025
What does this filing report?
An SEC Form 4 filing for 4D Molecular Therapeutics, Inc. records a stock award involving Stock Option (Right to Buy) on December 9, 2025. The reported quantity was 480,000. The filing date is December 11, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001650648
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 480,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 480,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 11, 2025, 4:18 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Humer Kristian ↗
Chief Financial Officer
CIK 0001872280
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 480,000
- Conversion / exercise price
- 10.51
- Exercise date
- Not reported
- Expiration date
- December 8, 2035
Filing footnotes & remarks
- F1
- 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.